Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Adherence to recommendations of Barrett's esophagus surveillance guidelines: a systematic review and meta-analysis.

Roumans CAM, van der Bogt RD, Steyerberg EW, Rizopoulos D, Lansdorp-Vogelaar I, Sharma P, Spaander MCW, Bruno MJ.

Endoscopy. 2019 Sep 17. doi: 10.1055/a-0995-0134. [Epub ahead of print]

PMID:
31529444
2.

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.

Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM, Lansdorp-Vogelaar I.

PLoS One. 2019 Sep 4;14(9):e0220234. doi: 10.1371/journal.pone.0220234. eCollection 2019.

3.

Incidence of Interval Colorectal Cancer After Negative Results From First-round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.

Toes-Zoutendijk E, Kooyker AI, Dekker E, Spaander MCW, Opstal-van Winden AWJ, Ramakers C, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, Nagtegaal ID, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I; Dutch national colorectal cancer screening working group.

Clin Gastroenterol Hepatol. 2019 Aug 20. pii: S1542-3565(19)30896-1. doi: 10.1016/j.cgh.2019.08.021. [Epub ahead of print]

4.

Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.

Grobbee EJ, van der Vlugt M, van Vuuren AJ, Stroobants AK, Mallant-Hent RC, Lansdorp-Vogelaar I, Bossuyt PMM, Kuipers EJ, Dekker E, Spaander MCW.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30890-0. doi: 10.1016/j.cgh.2019.08.015. [Epub ahead of print]

PMID:
31419575
5.

Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.

Schreuders EH, Grobbee EJ, Nieuwenburg SAV, Kapidzic A, van Roon AHC, van Vuuren AJ, Lansdorp-Vogelaar I, Spijker WWJ, Izelaar K, Bruno MJ, Kuipers EJ, Spaander MCW.

Lancet Gastroenterol Hepatol. 2019 Aug;4(8):622-631. doi: 10.1016/S2468-1253(19)30176-1. Epub 2019 Jun 10.

PMID:
31196734
6.

Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015.

Meester RGS, Mannalithara A, Lansdorp-Vogelaar I, Ladabaum U.

JAMA. 2019 May 21;321(19):1933-1934. doi: 10.1001/jama.2019.3076. No abstract available.

PMID:
31112249
7.

Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years.

Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellisé M, Esteban L, Kaminski MF, Suchanek S, Ngo O, Májek O, Leja M, Kuipers EJ, Spaander MC.

Gut. 2019 Oct;68(10):1820-1826. doi: 10.1136/gutjnl-2018-317592. Epub 2019 May 16.

8.

Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.

Gini A, Meester RGS, Keshavarz H, Oeffinger KC, Ahmed S, Hodgson DC, Lansdorp-Vogelaar I.

J Natl Cancer Inst. 2019 Apr 13. pii: djz060. doi: 10.1093/jnci/djz060. [Epub ahead of print]

PMID:
30980665
9.

Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections.

van Lanschot MCJ, van Leerdam ME, Lansdorp-Vogelaar I, Doets S, Nagtegaal ID, Schreurs HW, van der Hulst RWM, Carvalho B, Dekker E, Berkel AV.

Clin Gastroenterol Hepatol. 2019 Feb 22. pii: S1542-3565(19)30190-9. doi: 10.1016/j.cgh.2019.02.026. [Epub ahead of print]

PMID:
30802606
10.

Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests.

de Klerk CM, Wieten E, van der Steen A, Ramakers CR, Kuipers EJ, Hansen BE, Lansdorp-Vogelaar I, Bossuyt PM, Spaander MCW, Dekker E.

Am J Gastroenterol. 2019 Mar;114(3):511-518. doi: 10.14309/ajg.0000000000000148.

PMID:
30789417
11.

Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program.

Toes-Zoutendijk E, Bonfrer JMG, Ramakers C, Thelen M, Spaander MCW, Dekker E, van der Meulen MP, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Clin Chem. 2019 Mar;65(3):419-426. doi: 10.1373/clinchem.2018.294041. Epub 2019 Jan 16.

PMID:
30651228
12.

Evidence-based sizing of non-inferiority trials using decision models.

Lansdorp-Vogelaar I, Jagsi R, Jayasekera J, Stout NK, Mitchell SA, Feuer EJ.

BMC Med Res Methodol. 2019 Jan 7;19(1):3. doi: 10.1186/s12874-018-0643-2.

13.

Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.

de Klerk CM, Wieten E, Lansdorp-Vogelaar I, Bossuyt PM, Spaander MC, Dekker E.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):111-118. doi: 10.1016/S2468-1253(18)30319-4. Epub 2018 Nov 27.

PMID:
30497962
14.

Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.

Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I.

Med Decis Making. 2018 Nov;38(8):917-929. doi: 10.1177/0272989X18806497. Epub 2018 Oct 20.

PMID:
30343626
15.

The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.

Matthijsse SM, Naber SK, Hontelez JAC, Bakker R, van Ballegooijen M, Lansdorp-Vogelaar I, de Kok IMCM, de Koning HJ, van Rosmalen J, de Vlas SJ.

PLoS One. 2018 Sep 4;13(9):e0202924. doi: 10.1371/journal.pone.0202924. eCollection 2018.

16.

Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries.

Turnbull E, Priaulx J, de Kok IMCM, Lansdorp-Vogelaar I, Anttila A, Sarkeala T, Senore C, Segnan N, Csanádi M, Pitter J, Novak Mlakar D, Ivanus U, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1206-1211. doi: 10.1016/j.healthpol.2018.08.005. Epub 2018 Aug 24.

PMID:
30170757
17.

Overdiagnosis in Colorectal Cancer Screening: Time to Acknowledge a Blind Spot.

Kalager M, Wieszczy P, Lansdorp-Vogelaar I, Corley DA, Bretthauer M, Kaminski MF.

Gastroenterology. 2018 Sep;155(3):592-595. doi: 10.1053/j.gastro.2018.07.037. Epub 2018 Aug 1. No abstract available.

PMID:
30076834
18.

Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Heijnsdijk EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, Nielsen ME.

BJU Int. 2019 Feb;123(2):307-312. doi: 10.1111/bju.14502. Epub 2018 Aug 27.

19.

Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.

Wieten E, de Klerk CM, van der Steen A, Ramakers CR, Kuipers EJ, Hansen BE, Lansdorp-Vogelaar I, Bossuyt PM, Dekker E, Spaander MCW.

Gastroenterology. 2018 Nov;155(5):1392-1399.e5. doi: 10.1053/j.gastro.2018.07.021. Epub 2018 Jul 25.

PMID:
30055170
20.

Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.

Wieten E, Schreuders EH, Grobbee EJ, Nieboer D, Bramer WM, Lansdorp-Vogelaar I, Bruno MJ, Kuipers EJ, Spaander MCW.

Gut. 2019 May;68(5):873-881. doi: 10.1136/gutjnl-2017-315340. Epub 2018 Jun 22.

PMID:
29934436
21.

Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.

Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, Dwyer A, Ahnen DJ, Siegel RL, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2974-2985. doi: 10.1002/cncr.31542. Epub 2018 May 30.

22.

The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.

Peterse EFP, Meester RGS, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2964-2973. doi: 10.1002/cncr.31543. Epub 2018 May 30.

23.

Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.

Arrospide A, Idigoras I, Mar J, de Koning H, van der Meulen M, Soto-Gordoa M, Martinez-Llorente JM, Portillo I, Arana-Arri E, Ibarrondo O, Lansdorp-Vogelaar I.

BMC Cancer. 2018 Apr 25;18(1):464. doi: 10.1186/s12885-018-4362-1.

24.

Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.

Cenin DR, Naber SK, Lansdorp-Vogelaar I, Jenkins MA, Buchanan DD, Preen DB, Ee HC, O'Leary P.

J Gastroenterol Hepatol. 2018 Oct;33(10):1737-1744. doi: 10.1111/jgh.14154. Epub 2018 May 17.

25.

[National population screening for colorectal carcinoma in the Netherlands: results of the first years since the implementation in 2014].

Elferink MAG, Toes-Zoutendijk E, Vink GR, Lansdorp-Vogelaar I, Meijer GA, Dekker E, Lemmens VEPP.

Ned Tijdschr Geneeskd. 2018;162:D2283. Dutch.

PMID:
29519262
26.

Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs.

van der Meulen MP, Lansdorp-Vogelaar I, Goede SL, Kuipers EJ, Dekker E, Stoker J, van Ballegooijen M.

Radiology. 2018 Jun;287(3):901-911. doi: 10.1148/radiol.2017162359. Epub 2018 Feb 27.

27.

Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.

van der Vlugt M, Grobbee EJ, Bossuyt PM, Bos ACRK, Kuipers EJ, Lansdorp-Vogelaar I, Spaander MCW, Dekker E.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1237-1243.e2. doi: 10.1016/j.cgh.2018.01.037. Epub 2018 Feb 7.

PMID:
29427732
28.

Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.

Gastroenterology. 2017 Dec 27. pii: S0016-5085(17)36715-X. doi: 10.1053/j.gastro.2017.12.011. [Epub ahead of print]

PMID:
29288655
29.

Colorectal cancer screening in Australia.

Kuipers EJ, Lansdorp-Vogelaar I.

Lancet Public Health. 2017 Jul;2(7):e304-e305. doi: 10.1016/S2468-2667(17)30121-4. Epub 2017 Jun 26. No abstract available.

30.

Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I.

Health Aff (Millwood). 2017 Dec;36(12):2151-2159. doi: 10.1377/hlthaff.2017.0228.

31.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

32.

Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Feb;154(3):556-567.e18. doi: 10.1053/j.gastro.2017.10.036. Epub 2017 Nov 2.

33.

Stage distribution of screen-detected colorectal cancers in the Netherlands.

Toes-Zoutendijk E, Kooyker AI, Elferink MA, Spaander MCW, Dekker E, Koning HJ, Lemmens VE, van Leerdam ME, Lansdorp-Vogelaar I; LECO working group.

Gut. 2018 Sep;67(9):1745-1746. doi: 10.1136/gutjnl-2017-315111. Epub 2017 Oct 21. No abstract available.

PMID:
29055907
34.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

35.

Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer.

Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KAB, Zallen DT, Ganiats TG, Webber EM, Janssens ACJW, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Jan;154(1):105-116.e20. doi: 10.1053/j.gastro.2017.09.021. Epub 2017 Sep 28.

36.

Optimizing Patient Risk Stratification for Colonoscopy Screening and Surveillance of Colorectal Cancer: The Role for Linked Data.

Preen DB, Lansdorp-Vogelaar I, Ee HC, Platell C, Cenin DR, Troeung L, Bulsara M, O'Leary P.

Front Public Health. 2017 Sep 8;5:234. doi: 10.3389/fpubh.2017.00234. eCollection 2017. No abstract available.

37.

Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer.

Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I.

Int J Cancer. 2017 Dec 1;141(11):2359-2367. doi: 10.1002/ijc.30933. Epub 2017 Aug 31.

38.

Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15-39 Years in Western Australia 1982-2007: Examination of Colonoscopy History.

Troeung L, Sodhi-Berry N, Martini A, Malacova E, Ee H, O'Leary P, Lansdorp-Vogelaar I, Preen DB.

Front Public Health. 2017 Jul 24;5:179. doi: 10.3389/fpubh.2017.00179. eCollection 2017.

39.

Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.

Idigoras I, Arrospide A, Portillo I, Arana-Arri E, Martínez-Indart L, Mar J, de Koning HJ, Lastra R, Soto-Gordoa M, van der Meulen M, Lansdorp-Vogelaar I.

BMC Public Health. 2017 Aug 1;18(1):78. doi: 10.1186/s12889-017-4639-3. Erratum in: BMC Public Health. 2017 Sep 22;17 (1):736.

40.

Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.

Grobbee EJ, Schreuders EH, Hansen BE, Bruno MJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ.

Gastroenterology. 2017 Nov;153(5):1251-1259.e2. doi: 10.1053/j.gastro.2017.07.034. Epub 2017 Jul 29.

PMID:
28760383
41.

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):504-512.e11. doi: 10.1016/j.cgh.2017.07.011. Epub 2017 Jul 18.

42.

Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis.

Meulen MPV, Kapidzic A, Leerdam MEV, van der Steen A, Kuipers EJ, Spaander MCW, de Koning HJ, Hol L, Lansdorp-Vogelaar I.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1328-1336. doi: 10.1158/1055-9965.EPI-16-0786. Epub 2017 May 17.

43.

Fecal immunochemical test-based colorectal cancer screening: The gender dilemma.

Grobbee EJ, Wieten E, Hansen BE, Stoop EM, de Wijkerslooth TR, Lansdorp-Vogelaar I, Bossuyt PM, Dekker E, Kuipers EJ, Spaander MC.

United European Gastroenterol J. 2017 Apr;5(3):448-454. doi: 10.1177/2050640616659998. Epub 2016 Jul 14.

44.

Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.

van der Vlugt M, Grobbee EJ, Bossuyt PMM, Bos A, Bongers E, Spijker W, Kuipers EJ, Lansdorp-Vogelaar I, Spaander MCW, Dekker E.

Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5.

PMID:
28483499
45.

Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria.

van der Post RS, van Dieren J, Grelack A, Hoogerbrugge N, van der Kolk LE, Snaebjornsson P, Lansdorp-Vogelaar I, van Krieken JH, Bisseling TM, Cats A.

Gastrointest Endosc. 2018 Feb;87(2):397-404.e2. doi: 10.1016/j.gie.2017.04.016. Epub 2017 Apr 25.

PMID:
28455161
46.

Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.

Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, Yong JH, Kroep S, Tinmouth J, Lansdorp-Vogelaar I.

PLoS One. 2017 Mar 15;12(3):e0172864. doi: 10.1371/journal.pone.0172864. eCollection 2017.

47.

Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.

Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1397-1404.e7. doi: 10.1016/j.cgh.2017.02.017. Epub 2017 Feb 24.

48.

Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME.

BMC Cancer. 2017 Feb 7;17(1):112. doi: 10.1186/s12885-017-3089-8.

49.

Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis.

Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1471-1474. doi: 10.1016/j.cgh.2016.12.034. Epub 2017 Jan 12. No abstract available.

50.

Cost effectiveness of surveillance for GI cancers.

Omidvari AH, Meester RG, Lansdorp-Vogelaar I.

Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):879-891. doi: 10.1016/j.bpg.2016.09.001. Epub 2016 Sep 12. Review.

PMID:
27938783

Supplemental Content

Loading ...
Support Center